This study aimed to establish age- and sex-specific reference percentiles and z-scores for GLP-1, GIP, and glucagon in children and to examine their associations with insulin resistance, lipid ...
Objective To examine whether fasting and stimulated glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) concentrations differ between children and adolescents with obesity and insulin resistance (OIR), obesity and normal insulin sensitivity (OIS), and controls with normal weight (NW).
nimal and cellular studies into GLP-1 receptor agonism of the pancreatic beta cell, have shown that it results in: the expression of insulin gene and insulin synthesis; enhanced glucose-stimulated insulin secretion; restored glucose sensitivity in previously glucose-resistant beta cells; and stimulating beta cell proliferation, survival and ...
Family medicine clinicians initiating or titrating GLP-1 receptor agonist therapy rely on dynamic assessment of insulin resistance rather than single-point measurements, and epigenetic markers that track IR trajectories from childhood offer a biologically grounded basis for identifying which patients carry the highest cumulative metabolic burden before they present for adult care ...
Q: How Do GLP-1 Receptor Agonists Work in Pediatric Diabetes Care? GLP-1 receptor agonists provide targeted control for type 2 diabetes and obesity in children by delaying gastric emptying, slowing glucose absorption; reducing appetite and promoting weight loss, as well as lowering glucagon levels, which improves blood sugar control. These mechanisms address insulin resistance more directly ...
